About FDALive
FDALive.com Pricing Information
Videoconferencing: $1800
Audioconference: $400
Webcast:
· Single Viewer $140 - $250
· Group $800 - $1,200
CD-ROM:
· DPi (Image of Slides on CD): $400.00 for each meeting day purchased.
· DPv (Interactive Video CD): $500.00 for each meeting day purchased.
· DPvi (Interactive Slides & Video): $1,000.00 for each meeting day purchased.
DVD Format:
· $400 for 1 meeting day purchased.
· $800 for 2 meeting days purchased.
· $1,200 for 3 meeting days purchased.
Transcripts:
3 Business Day Services: $1800 - $2200
Group and Volume Discount Rates Available…
Contact for Quote…
Upcoming Meetings
Cardiovascular and Renal Drugs AdComm
Meeting Date: 12/10/19-12/10/19
Meeting Details:
The committee will be asked to discuss new drug application (NDA) 022034, for vernakalant HCl solution, for intravenous injection, submitted by Correvio International Sàrl, for the proposed indication of rapid conversion of recent onset atrial fibrillation to sinus rhythm for non-surgery patients: Atrial fibrillation = 7 days duration, and for post-cardiac surgery patients: Atrial fibrillation = 3 days duration.
| Location: | FDA White Oak | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
Recent Meetings
Endocrinologic and Metabolic Drugs AdComm - Sponsor: Amarin Pharma Inc.
Meeting Date: 11/14/19-11/14/19
Meeting Details:
The committee will discuss supplemental new drug application 202057/S-035, for VASCEPA (icosapent ethyl) capsules for oral administration, sponsored by Amarin Pharma Inc., for the following proposed indication: To reduce the risk of cardiovascular events, as an adjunct to statin therapy in adult patients with elevated triglycerides levels (135 mg/dL or greater) and other risk factors for cardiovascular disease, based on the results of a clinical study entitled “A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin. The Primary Objective is to Evaluate the Effect of 4 g/Day AMR101 for Preventing the Occurrence of a First Major Cardiovascular Event. (REDUCE-IT)”
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Immunology Devices Panel
Meeting Date: 11/13/19-11/14/19
Meeting Details:
On November 13 and 14, 2019, the committee will discuss the topic of immunological responses to metal-containing products regulated as medical devices. The discussion will focus on metal-containing implants as well as dental amalgam. Implants are medical devices that are placed into a surgically or naturally formed opening of the human body and are intended to remain there after the procedure for an extended period of time (typically, greater than 30 days). For decades, metal-containing implants have been used in a large number of medical specialties including cardiology, orthopedics, dentistry, gastroenterology, and neurology or neurosurgery. Recent postmarket issues with some metal-on-metal orthopedic implants and gynecological metal-containing implants have raised questions about the potential for some patients to develop unexpected or heightened biological responses to the implant. These may include local (peri-implant) adverse events and potentially systemic manifestations, which may impact a patient's quality of life and necessitate medical or surgical intervention. While not considered an implant, dental amalgam is included in this discussion because of its potential for patient and user exposure to mercury compounds and some purported similarities in the adverse biological responses and clinical manifestations elicited by some dental amalgams to that of traditional metal implants.
| Location: | Gaithersburg, MD | Related News Links: | Not Available |
| Time: | 8:00AM-6:00PM | ||
| Materials: | |||
- Endocrinologic and Metabolic Drugs AdComm - Sponsor: Boehringer Ingelheim
Meeting Date: 11/13/19-11/13/19
Meeting Details:
The committee will discuss supplemental new drug application (sNDA) 204629/S-020 for empagliflozin oral tablet, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the following proposed indication: As an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Vaccines and Related Biological Products
Meeting Date: 11/8/19-11/8/19
Meeting Details:
On November 8, 2019, the Center for Biologics Evaluation and Research's (CBER) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet in open session to discuss and make recommendations on the development of chikungunya vaccines.
| Location: | The Great Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- General Hospital and Personal Use Devices Panel
Meeting Date: 11/6/19-11/7/19
Meeting Details:
On November 6 and 7, 2019, the committee will discuss the topic of industrial ethylene oxide (EtO) sterilization of medical devices and its role in maintaining public health as well as the risks of infection with reprocessed duodenoscopes. Subject matter of the panel meeting will include potential methods and expert assessment of how to reduce EtO emissions to the environment from medical device sterilization processes without compromising assurance of sterility or effective processing of medical devices. The panel will also discuss recommendations to reduce the risk of infection from reprocessed duodenoscopes.
| Location: | Gaithersburg MD | Related News Links: | Not Available |
| Time: | 8:00AM-6:00PM | ||
| Materials: | |||
- Bone, Reproductive and Urologic AdComm
Sponsor: Agile Therapeutics, Inc.
Meeting Date: 10/30/19-10/30/19
Meeting Details:
The committee will discuss new drug application (NDA) 204017 (levonorgestrel and ethinyl estradiol) transdermal system, submitted by Agile Therapeutics, Inc., for the prevention of pregnancy in women of reproductive potential.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
- Bone, Reproductive and Urologic Drugs AdComm
Sponsor: AMAG Pharmaceuticals
Meeting Date: 10/29/19-10/29/19
Meeting Details:
The committee will discuss supplemental new drug application (sNDA 021945/S-023#) for MAKENA (hydroxyprogesterone caproate injection, 250 milligrams per milliliter) manufactured by AMAG Pharmaceuticals. In 2011, MAKENA received approval under the accelerated approval pathway (21 CFR part 314, subpart H, and section 506(c) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356(c)) for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MAKENA was shown in the preapproval clinical trial to reduce the proportion of women who delivered at less than 37 weeks gestation, a surrogate endpoint that FDA determined was reasonably likely to predict a clinical benefit of preterm birth prevention, such as improved neonatal mortality and morbidity. As required under 21 CFR 314.510, the Applicant conducted a postapproval confirmatory clinical trial to verify and describe clinical benefit. AMAG Pharmaceuticals has disclosed that this completed confirmatory trial did not demonstrate a statistically significant difference between the treatment and placebo arms for the co-primary endpoints of reducing the risk of recurrent preterm birth or improving neonatal mortality and morbidity. The committee will consider the trial's findings and the sNDA in the context of AMAG Pharmaceuticals' confirmatory study obligation.
| Location: | FDA Meeting Room | Related News Links: | Not Available |
| Time: | 8:00AM-5:00PM | ||
| Materials: | |||
Past Meetings
Below is a listing of all committees. Select a committee to display all meetings available for that committee.
Live Meetings
There are no Live Broadcasts available at this time.
Sign in to FDALive
My Shopping Cart
FDA
FDA
About FDALive